Netherlands

SkylineDx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

BioInvent and SkylineDx to Collaborate on Patient Stratification to Maximize Impact of Treatment with BI-1206

Lead Product(s): BI-1206,Rituximab,Pembrolizumab

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: BioInvent

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 24, 2020

Details:

The companies will research and develop predictive immunological signatures identify patients with non-Hodgkin lymphoma and solid cancers who are likely to show clinical responses to BI-1206.

Kiadis Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Kiadis Pharma announces new data on ex-vivo FC21

Lead Product(s): Natural killer cells,Filgrastim,Fludarabine

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2020

Details:

The abstract showcases the potential of the Company’s NK cell therapy to treat relapsed/refractory acute myeloid leukemia (R/R AML).

Kiadis Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML

Lead Product(s): K-NK003,Cytarabine,Decitabine

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 26, 2020

Details:

The trial is expected to provide further clinical proof-of-concept of Kiadis’ K-NK003 product.

Find

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Product Type

Companies

SkylineDx

BioInvent and SkylineDx to Collaborate on Patient Stratification to Maximize Impact of Treatment with BI-1206

Kiadis Pharma

Kiadis Pharma announces new data on ex-vivo FC21

Kiadis Pharma

Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML